- Accession Number
Derivatives of phosphatidic acid in which the hydrophobic regions are composed of two fatty acids and a polar alcohol is joined to the C-3 position of glycerol through a phosphodiester bond. They are named according to their polar head groups, such as phosphatidylcholine and phosphatidylethanolamine.
Drug Drug Description Phosphatidyl serine A nutrient used in some supplement products. Lecithin Fatty substances commonly found in nutritional supplements. Choline alfoscerate A natural choline that is used to manage declining cognitive function associated with neurodegenerative and vascular diseases. 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine Not Available Platelet Activating Factor Not Available sn-glycero-3-phosphoethanolamine Not Available Cadaverine Cadaverine is a foul-smelling diamine formed by bacterial decarboxylation of lysine. Phosphatidylethanolamine Not Available L-Dilinoleoyllecithin Not Available Lucinactant Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. ETC-588 Investigated for use/treatment in atherosclerosis, coronary artery disease, and vascular diseases. Colfosceril palmitate A pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. DL-dimyristoylphosphatidylcholine DL-dimyristoylphosphatidylcholine is not an active pharmaceutical agent and has no indication. DL-dimyristoylphosphatidylglycerol DL-dimyristoylphosphatidylglycerol is not an considered an active pharmacological ingredient in pharmaceutical preparations and so has no official indications. Mifamurtide A muramyl dipeptide derivative used to treat high grade, resectable, non-metastatic osteosarcoma after surgical resection. 1,2-Distearoyllecithin Not Annotated VB-201 VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis). Iopofosine I-131 Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).
- Drugs & Drug Targets